When the immunotherapeutic efficacy of PC61 and anti-CTLA-4 treatment in conjunction with E6-RHDV-VLP-PADRE immunization was compared, both treatments were comparable in their ability to reduce tumour area (M-W U test; ns) and enhance survival (M-C test; ns). The gene discussed is CTLA4; the disease is neoplasm.